JP2015522630A5 - - Google Patents

Info

Publication number

JP2015522630A5

JP2015522630A5 JP2015523453A JP2015523453A JP2015522630A5 JP 2015522630 A5 JP2015522630 A5 JP 2015522630A5 JP 2015523453 A JP2015523453 A JP 2015523453A JP 2015523453 A JP2015523453 A JP 2015523453A JP 2015522630 A5 JP2015522630 A5 JP 2015522630A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

composition according

biotin

multiple sclerosis

treatment

Prior art date

2013-04-29

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 32
• 239000008194 pharmaceutical composition Substances 0.000 claims 26
• 239000011616 biotin Substances 0.000 claims 16
• 229960002685 biotin Drugs 0.000 claims 16
• 235000020958 biotin Nutrition 0.000 claims 16
• 201000006417 multiple sclerosis Diseases 0.000 claims 15
• 229940079593 drug Drugs 0.000 claims 8
• 239000003814 drug Substances 0.000 claims 8
• NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 claims 2
• 108010072051 Glatiramer Acetate Proteins 0.000 claims 2
• 102000003996 Interferon-beta Human genes 0.000 claims 2
• 108090000467 Interferon-beta Proteins 0.000 claims 2
• FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims 2
• 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims 2
• 229960004979 fampridine Drugs 0.000 claims 2
• 229960000556 fingolimod Drugs 0.000 claims 2
• KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims 2
• 229960003776 glatiramer acetate Drugs 0.000 claims 2
• 239000003018 immunosuppressive agent Substances 0.000 claims 2
• 229960001388 interferon-beta Drugs 0.000 claims 2
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 2
• 229960001156 mitoxantrone Drugs 0.000 claims 2
• 239000000203 mixture Substances 0.000 claims 2
• 229960005027 natalizumab Drugs 0.000 claims 2
• 239000000546 pharmaceutical excipient Substances 0.000 claims 2
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
• 239000004480 active ingredient Substances 0.000 claims 1
• 239000002775 capsule Substances 0.000 claims 1
• 230000002519 immonomodulatory effect Effects 0.000 claims 1
• 239000002955 immunomodulating agent Substances 0.000 claims 1
• 229940121354 immunomodulator Drugs 0.000 claims 1
• 230000002584 immunomodulator Effects 0.000 claims 1
• 229960003444 immunosuppressant agent Drugs 0.000 claims 1
• 230000001861 immunosuppressant effect Effects 0.000 claims 1
• 229940125721 immunosuppressive agent Drugs 0.000 claims 1
• 238000002347 injection Methods 0.000 claims 1
• 239000007924 injection Substances 0.000 claims 1
• 239000008101 lactose Substances 0.000 claims 1
• 239000007937 lozenge Substances 0.000 claims 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
• 239000008108 microcrystalline cellulose Substances 0.000 claims 1
• 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
• 230000000926 neurological effect Effects 0.000 claims 1
• 239000006187 pill Substances 0.000 claims 1
• 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims 1
• 201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims 1
• 238000013268 sustained release Methods 0.000 claims 1
• 239000012730 sustained-release form Substances 0.000 claims 1
• 239000003826 tablet Substances 0.000 claims 1
• 239000000454 talc Substances 0.000 claims 1
• 229910052623 talc Inorganic materials 0.000 claims 1
• 230000004304 visual acuity Effects 0.000 claims 1